"At Bellaire Dermatology, we are committed to providing the finest care through individual attention and progressive treatment strategies in the fields of Medical and Cosmetic Dermatology."

During the past decade, Bellaire Dermatology Associates conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 13 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 11 clinical trials were completed. i.e. 91.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Bellaire Dermatology Associates" #1 sponsor was "Eli Lilly and Company" with 8 trials, followed by "Medy-Tox" with 3 trials sponsored, "Allergan" with 2 trials sponsored, "Astellas Pharma Inc" with 2 trials sponsored and "Bristol-Myers Squibb" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Bellaire Dermatology Associates" #1 collaborator was "Dermira, Inc." with 3 trials as a collaborator, "Incyte Corporation" with 3 trials as a collaborator and "Biogen" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Bellaire Dermatology Associates" are "Atopic Dermatitis" (10 trials), "Lateral Canthal Lines" (3 trials), "Psoriasis" (3 trials), "Acne Vulgaris" (2 trials) and "Alopecia Areata" (2 trials). Many other conditions were trialed in "Bellaire Dermatology Associates" in a lesser frequency.

Most popular intervention types in "Bellaire Dermatology Associates" are "Drug" (22 trials), "Biological" (6 trials), "Device" (4 trials), "Other" (4 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Lebrikizumab" (4 trials), "Baricitinib" (3 trials), "MT10109L" (3 trials) and "BMS-986165" (2 trials). Other intervention names were less common.

The vast majority of trials in "Bellaire Dermatology Associates" are 29 trials for "All" genders.

Currently, there are NaN active trials in "Bellaire Dermatology Associates". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Bellaire Dermatology Associates, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Bellaire Dermatology Associates, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".